Bristol-Myers Squibb Net Tangible Assets

Bristol-Myers Squibb (BMY) currently reports a net tangible assets of $22B as of June 2026. That compares with $63B in the prior-year period — down 64.5% year over year. Use the charts on this page to explore Bristol-Myers Squibb's net tangible assets history and peer comparisons.

Bristol-Myers Squibb's net tangible assets decreased from $63B to $22B — a 64.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bristol-Myers Squibb reported $22B in net tangible assets as of June 2026. That compares with $63B in the prior-year period — down 64.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $22B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bristol-Myers Squibb, and consider following BMY for alerts when major investors trade the stock.

Bristol-Myers Squibb is classified in the Healthcare sector. On net tangible assets, it currently shows $22B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BMY with unrelated industries.